tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Uremia D014511 33 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Stomach Ulcer D013276 75 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Hypercalcemia D006934 13 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Cacciarelli TV et al. An analysis of pretransplantation variables associated with long-term allograft outcome in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. 1999 Transplantation pmid:10507484
Morrissey PE Prope tolerance: is it the end or the means? 2009 Transplantation pmid:19502973
Alloway RR Mounting Clinical Evidence With Tacrolimus Generic Products. 2017 Transplantation pmid:28749820
Prókai Á et al. Calcineurin-inhibition Results in Upregulation of Local Renin and Subsequent Vascular Endothelial Growth Factor Production in Renal Collecting Ducts. 2016 Transplantation pmid:26502369
Lykavieris P et al. Angioedema in pediatric liver transplant recipients under tacrolimus immunosuppression. 2003 Transplantation pmid:12544888
Moffatt SD et al. Potential for improved therapeutic index of FK506 in liposomal formulation demonstrated in a mouse cardiac allograft model. 1999 Transplantation pmid:10342309
Woodle ES et al. FK506--reversal of humorally mediated cardiac allograft rejection in the presence of preformed anti-class I antibody. 1993 Transplantation pmid:7504346
Yin DP et al. Lewis rat pancreas, but not cardiac xenografts, are resistant to anti-gal antibody mediated hyperacute rejection. 2001 Transplantation pmid:11391223
Eberhard OK et al. How best to use tacrolimus (FK506) for treatment of steroid- and OKT3-resistant rejection after renal transplantation. 1996 Transplantation pmid:8629294
Bruce DS et al. Multicenter survey of daclizumab induction in simultaneous kidney-pancreas transplant recipients. 2001 Transplantation pmid:11726823
Loucaidou M et al. Five-year results of kidney transplantation under tacrolimus-based regimes: the persisting significance of vascular rejection. 2003 Transplantation pmid:14557763
Muthukumar T et al. HIV-infected kidney graft recipients managed with an early corticosteroid withdrawal protocol: clinical outcomes and messenger RNA profiles. 2013 Transplantation pmid:23503504
King-Biggs MB et al. Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation. 2003 Transplantation pmid:12792493
Hricik DE et al. Long-term graft outcomes after steroid withdrawal in African American kidney transplant recipients receiving sirolimus and tacrolimus. 2007 Transplantation pmid:17297401
Roberts JP et al. Reversal of chronic rejection after treatment failure with FK506 and RS61443. 1993 Transplantation pmid:7692634
Cacciarelli TV et al. Oral tacrolimus (FK506) induction therapy in pediatric orthotopic liver transplantation. 1996 Transplantation pmid:8610416
Jain A et al. Comparative long-term evaluation of tacrolimus and cyclosporine in pediatric liver transplantation. 2000 Transplantation pmid:10972220
Sharif A et al. Insulin resistance indexes in renal transplant recipients maintained on tacrolimus immunosuppression. 2010 Transplantation pmid:20145524
Abu-Qaoud MS et al. Lack of relationship between microvascular and macrovascular disease in heart transplant recipients. 2012 Transplantation pmid:23044666
Kaplan B et al. Frequency of hyperkalemia in recipients of simultaneous pancreas and kidney transplants with bladder drainage. 1996 Transplantation pmid:8900321
Woodward RS et al. Renal graft survival and calcineurin inhibitor. 2005 Transplantation pmid:16177637
Gruber SA et al. Initial results of solitary pancreas transplants performed without regard to donor/recipient HLA mismatching. 2000 Transplantation pmid:10933170
Shapiro R et al. Alopecia as a consequence of tacrolimus therapy. 1998 Transplantation pmid:9603186
Fernandez LA et al. The effects of maintenance doses of FK506 versus cyclosporin A on glucose and lipid metabolism after orthotopic liver transplantation. 1999 Transplantation pmid:10589951
Kadry Z et al. Kaposi's sarcoma in liver transplant recipients on FK506. 1998 Transplantation pmid:9583882
Batten P et al. Human T cell responses to human and porcine endothelial cells are highly sensitive to cyclosporin A and FK506 in vitro. 1999 Transplantation pmid:10589954
Uemura T et al. Single dose of alemtuzumab induction with steroid-free maintenance immunosuppression in pancreas transplantation. 2011 Transplantation pmid:21841541
Jacobson PA et al. Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium. 2011 Transplantation pmid:21206424
Ko S et al. The enhanced immunosuppressive efficacy of newly developed liposomal FK506 in canine liver transplantation. 1995 Transplantation pmid:7539553
Fealy MJ et al. Association of down-regulation of cytokine activity with rat hind limb allograft survival. 1995 Transplantation pmid:7539555
Yang H et al. Liposomal encapsulation significantly enchances the immunosuppressive effect of tacrolimus in a discordant islet xenotransplant model. 2002 Transplantation pmid:11907415
St A Nunes FA and Lucey MR Searching for a balance when applying immunosuppression after liver transplantation. 2001 Transplantation pmid:11258425
Opelz G and Döhler B Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation. 2009 Transplantation pmid:19300179
Rostambeigi N et al. Unique cellular and mitochondrial defects mediate FK506-induced islet β-cell dysfunction. 2011 Transplantation pmid:21200364
Mikhalski D et al. Cold ischemia is a major determinant of acute rejection and renal graft survival in the modern era of immunosuppression. 2008 Transplantation pmid:18401260
Gibson SW et al. Nutritional immunomodulation leads to enhanced allograft survival in combination with cyclosporine A and rapamycin, but not FK506. 2000 Transplantation pmid:10852592
Ciancio G et al. A randomized pilot study of donor stem cell infusion in living-related kidney transplant recipients receiving alemtuzumab. 2013 Transplantation pmid:23903014
Lerut J et al. Anti-CD2 monoclonal antibody and tacrolimus in adult liver transplantation. 2005 Transplantation pmid:16314784
Komori K et al. The role of graft and host accommodation in a hamster-to-rat cardiac transplantation model. 2008 Transplantation pmid:18192920
Meiser BM et al. Tacrolimus or cyclosporine: which is the better partner for mycophenolate mofetil in heart transplant recipients? 2004 Transplantation pmid:15446320
Uemoto S et al. Experience with FK506 in living-related liver transplantation. 1993 Transplantation pmid:7679528
Murase N et al. FK 506 prevents spontaneous diabetes in the BB rat. 1991 Transplant. Proc. pmid:1703705
Lauzurica R et al. Subclinical inflammation in renal transplant recipients: impact of cyclosporine microemulsion versus tacrolimus. 2007 Transplant. Proc. pmid:17889127
Manzanares C et al. Influence of hepatitis C virus infection on FK 506 blood levels in renal transplant patients. 1998 Transplant. Proc. pmid:9636513
Pérez-Flores I et al. Intracellular ATP levels in CD4+ lymphocytes are a risk marker of rejection and infection in renal graft recipients. 2009 Jul-Aug Transplant. Proc. pmid:19715845
Spinelli GA et al. Lipid profile changes during the first year after kidney transplantation: risk factors and influence of the immunosuppressive drug regimen. 2011 Transplant. Proc. pmid:22172836
Urbizu JM et al. Immunosuppression using tacrolimus/mycophenolate versus neoral/mycophenolate following kidney transplantation: a single-center experience. 2002 Transplant. Proc. pmid:11959197
Mac Guad R et al. Effects of CYP3A5 Genetic Polymorphism on the Pharmacokinetics of Tacrolimus in Renal Transplant Recipients. Transplant. Proc. pmid:26915847
Staschak S et al. A cost comparison of liver transplantation with FK 506 or CyA as the primary immunosuppressive agent. 1990 Transplant. Proc. pmid:1689896
Zeevi A et al. Comparative in vitro studies on the immunosuppressive effects of purine and pyrimidine synthesis inhibitors. 1993 Transplant. Proc. pmid:7679843
Wakizaka Y et al. Xenotransplantation of hamster liver into Gunn rats reserves congenital hyperbilirubinemia. 1996 Transplant. Proc. pmid:8623372
Chueh SC et al. Drug fever caused by mycophenolate mofetil in a renal transplant recipient--a case report. 2000 Transplant. Proc. pmid:11120003
Ueno T et al. Renal dysfunction following adult intestinal transplant under tacrolimus-based immunosuppression. 2006 Jul-Aug Transplant. Proc. pmid:16908274
Bora F et al. Drug interaction between tacrolimus and ertapenem in renal transplantation recipients. 2012 Transplant. Proc. pmid:23195020
Crespo-Leiro MG Calcineurin inhibitors in heart transplantation. 2005 Transplant. Proc. pmid:16386614
Rucay P et al. FK 506 as treatment of late acute rejection in liver transplant patients. 1995 Transplant. Proc. pmid:7533354
Katz HR et al. Mast cell biochemical and functional heterogeneity. 1991 Transplant. Proc. pmid:1721308
Oppenheimer F Steroid withdrawal in renal transplant recipients. 2000 Transplant. Proc. pmid:10686314
Tamura A et al. Combination effect of tacrolimus and FTY720 in liver transplantation in rats. 1999 Transplant. Proc. pmid:10578290
Florman S et al. Conversion of stable liver transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified release tacrolimus-based regimen. 2005 Transplant. Proc. pmid:15848672
Niederstadt C et al. Effect of FK506 on magnesium homeostasis after renal transplantation. 1997 Transplant. Proc. pmid:9365709
Chen JW et al. Ten-year results of a randomised prospective study of FK506 versus cyclosporine in management of primary orthotopic liver transplantation. 2002 Transplant. Proc. pmid:12176460
Fukuzaki T et al. Induction of unresponsiveness to islet allografts with donor spleen cell inoculation followed by a single injection of FK 506. 1995 Transplant. Proc. pmid:7533407
Rucay P et al. FK 506 rescue therapy for refractory acute rejection in five liver recipients. 1991 Transplant. Proc. pmid:1721340
Mortensen DM et al. Calcineurin activity in tacrolimus-treated renal transplant patients early after and 5 years after transplantation. 2006 Transplant. Proc. pmid:17098028
Loucaidou M et al. Late steroid withdrawal for renal transplant recipients on tacrolimus and MMF is safe. 2005 Transplant. Proc. pmid:15919469
Malyszko J et al. A possible role of hepcidin in the pathogenesis of anemia among kidney allograft recipients. 2009 Transplant. Proc. pmid:19857675
Costa A et al. Small bowel myoelectrical activity after transplantation in pigs: motility versus ACR score. 1997 Transplant. Proc. pmid:9142281
Kitamura M et al. Clinical experience of FK 506 for renal allograft transplantation. 1994 Transplant. Proc. pmid:7520611
Hung CM et al. Tacrolimus to rescue refractory hepatic allograft rejection: a collaborative study in Taiwan. 1998 Transplant. Proc. pmid:9838572
Fung JJ et al. Adverse effects associated with the use of FK 506. 1991 Transplant. Proc. pmid:1721372
Omar G et al. FK 506 inhibition of cyclosporine metabolism by human liver microsomes. 1991 Transplant. Proc. pmid:1703356
Miller J Tacrolimus and mycophenolate mofetil in renal transplant recipients: one year results of a multicenter, randomized dose ranging trial. FK506/MMF Dose-Ranging Kidney Transplant Study Group. 1999 Feb-Mar Transplant. Proc. pmid:10083106
Busuttil RW and Holt CD Tacrolimus (FK506) is superior to cyclosporine in liver transplantation. 1997 Feb-Mar Transplant. Proc. pmid:9123119
Cho WH et al. Basiliximab does not reduce the early rejection incidence in high-risk kidney recipients under tacrolimus-based immunosuppression. 2008 Transplant. Proc. pmid:18790201
Kim JD et al. Single-Center Experience of ABO-Incompatible Living-Donor Liver Transplantation With a New Simplified Intravenous Immunoglobulin Protocol: A Propensity Score-Matching Analysis. 2016 Transplant. Proc. pmid:27320573
Weinbroum AA et al. Lack of cumulative effect of tacrolimus and low flow on a rat isolated liver. 2001 Transplant. Proc. pmid:11543812
Jacobs TW et al. The effect of FK 506, cyclosporine A, and cyclosporine G on serum 1,25-dihydroxyvitamin D levels. 1991 Transplant. Proc. pmid:1721403
Yoshimura R et al. A comparative study of cyclosporine vs FK 506: role of kidney microsomal cytochrome P-450. 1992 Transplant. Proc. pmid:1379755
Baruch Y et al. Anasarca and hypertrophic cardiomyopathy in a liver transplant patient on FK506: relieved after a switch to Neoral. 1996 Transplant. Proc. pmid:8769215
Zuckermann A et al. Benefit of mycophenolate mofetil in patients with cyclosporine A-induced nephropathy after lung transplantation. 1999 Feb-Mar Transplant. Proc. pmid:10083518
Arai K et al. Prolonged limb allograft survival with short-term treatment with FK-506 in rats. 1989 Transplant. Proc. pmid:2468256
Ohdan H et al. Prolongation of hamster-to-rat liver xenograft survival by donor bone marrow augmentation. 1997 Feb-Mar Transplant. Proc. pmid:9123589
Langrehr JM et al. Quadruple versus dual tacrolimus-based induction after liver transplantation: a prospective, randomized trial. 2001 Transplant. Proc. pmid:11377549
Uber PA et al. Steroid weaning in heart transplantation is associated with decreased B-type natriuretic peptide: surrogate evidence for cardiac adaptation. 2002 Transplant. Proc. pmid:12176598
Wada H et al. An attempt to induce tolerance to skin grafts in congenic mice with FK 506. 1991 Transplant. Proc. pmid:1721435
Ghio L et al. Conversion from tacrolimus to cyclosporine for a non-dose-dependent tacrolimus-induced toxicity, a pediatric kidney transplant recipient case report. 2004 Transplant. Proc. pmid:15251325
Calne R et al. Observations about FK-506 in primates. 1987 Transplant. Proc. pmid:2445078
Halloran PF et al. Calcineurin and the biological effect of cyclosporine and tacrolimus. 1998 Transplant. Proc. pmid:9723430
Renner FC et al. The risk of polyomavirus-associated graft nephropathy is increased by a combined suppression of CD8 and CD4 cell-dependent immune effects. 2013 Transplant. Proc. pmid:23726630
Walgenbach KJ et al. Upregulation of basic fibroblast growth factor during chronic rejection of rat intestinal allografts and its downregulation by FK 506. 1998 Transplant. Proc. pmid:9745501
Laftavi MR et al. The role of antibiotic prophylaxis in the new era of immunosuppression. 2011 Transplant. Proc. pmid:21440753
Jordan ML et al. Steroid withdrawal for pancreas transplants under tacrolimus immunosuppression. 2001 Feb-Mar Transplant. Proc. pmid:11267456
Konno O et al. Early Outcomes of Living-Donor Kidney Transplantation With Immunosuppression Therapy Induction With Tacrolimus Extended-Release: A Comparison With Cyclosporine. 2018 Transplant. Proc. pmid:30316378
Li S et al. Intrathymic inoculation of donor bone marrow at the time of transplantation plus a short course of tacrolimus induce long-term acceptance to rat lung allografts. 1998 Transplant. Proc. pmid:9636431
Pinho-Apezzato ML et al. Multiple clinical presentations of lymphoproliferative disorders in pediatric liver transplant recipients: a single-center experience. 2010 Transplant. Proc. pmid:20620519
Suarez Benjumea A et al. Hepatitis C Virus in Kidney Transplant Recipients: A Problem on the Path to Eradication. 2016 Transplant. Proc. pmid:27932111
Rathi M et al. Conversion from tacrolimus to cyclosporine in patients with new-onset diabetes after renal transplant: an open-label randomized prospective pilot study. 2015 Transplant. Proc. pmid:26036543
Henley SE et al. Lipids following pancreas transplantation in recipients receiving FK 506. 1995 Transplant. Proc. pmid:8539809
Pridöhl O et al. Low-dose immunosuppression with FK 506 and sirolimus after liver transplantation: 1-year results. 2001 Nov-Dec Transplant. Proc. pmid:11750384